Work

Supplemental Table 4 from Phase 1 Study of KITE-222, an Autologous CLL-1–Directed CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Cites:
Cited by:
Related to: 10